MARKET

AXGN

AXGN

Axogen Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.50
+0.41
+2.55%
Closed 16:00 09/27 EDT
OPEN
16.12
PREV CLOSE
16.09
HIGH
16.74
LOW
15.90
VOLUME
132.00K
TURNOVER
--
52 WEEK HIGH
23.94
52 WEEK LOW
11.04
MARKET CAP
683.05M
P/E (TTM)
-30.4372
1D
5D
1M
3M
1Y
5Y
Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
Industry leading nerve repair surgeons will share best practices and case studies during symposium sessionALACHUA, Fla. and TAMPA, Fla., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative ...
GlobeNewswire · 5d ago
BRIEF-Axogen Recon(SM) Clinical Study Completes Subject Follow-Up
reuters.com · 09/01 11:25
Axogen RECON Clinical Study Completes Subject Follow-up
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON Clinical Study supporting its
Benzinga · 09/01 11:04
AxoGen Clinical Study Completes Avance Nerve Graft Subject Follow-Up, on Track to Receive Data Readout in 2022
MT Newswires · 09/01 08:07
Could The AxoGen, Inc. (NASDAQ:AXGN) Ownership Structure Tell Us Something Useful?
A look at the shareholders of AxoGen, Inc. ( NASDAQ:AXGN ) can tell us which group is most powerful. Generally...
Simply Wall St. · 08/18 10:35
MedTech stocks slump after Texas Governor urged hospitals to delay elective procedures
The shares of medical device makers have come under pressure in morning hours after Texas Governor Greg Abbott encouraged the hospitals to consider postponing certain elective medical procedures to make
Seekingalpha · 08/10 15:54
Axogen Inc (AXGN) CEO Karen L. Zaderej Sold $757,270 of Shares
GuruFocus News · 08/10 04:53
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/04 21:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXGN. Analyze the recent business situations of Axogen Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
28.57%Buy
28.57%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AXGN stock price target is 27.00 with a high estimate of 31.00 and a low estimate of 24.00.
High31.00
Average27.00
Low24.00
Current 16.50
EPS
Actual
Estimate
-0.12-0.08-0.030.01
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 214
Institutional Holdings: 43.61M
% Owned: 105.35%
Shares Outstanding: 41.40M
TypeInstitutionsShares
Increased
39
2.41M
New
21
1.31M
Decreased
41
2.10M
Sold Out
15
835.05K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.19%
Healthcare Equipment & Supplies
-1.88%
Key Executives
Chairman/President/Chief Executive Officer/Director
Karen Zaderej
Chief Financial Officer
Peter Mariani
Chief Human Resource Officer
Maria Martinez
Chief Compliance Officer/General Counsel
Brad Ottinger
Vice President - Operations
Mike Donovan
Vice President
Erick DeVinney
Vice President
Mark Friedman
Other
Isabelle Billet
Other
Eric Sandberg
Other
Angelo Scopelianos
Lead Director/Independent Director
Amy Wendell
Director
John Johnson
Independent Director
Quentin Blackford
Independent Director
Gregory Freitag
Independent Director
Mark Gold
Independent Director
Alan Levine
Independent Director
Guido Neels
Independent Director
Paul Thomas
Declaration Date
Dividend Per Share
Ex-Div Date
12/21/2009
Dividend USD 1
01/27/2010
--
Dividend USD 0.06
02/23/2005
About AXGN
AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.

Webull offers kinds of AxoGen Inc stock information, including NASDAQ:AXGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXGN stock methods without spending real money on the virtual paper trading platform.